The proposed research project is focused on the identification of modulators of a newly described PARP1-MGMT protein-protein interaction, which is demonstrated to enhance DNA repair through pathway crosstalk. Our ultimate goal is to develop a novel targeted therapy for cancers dependent on these pathways. Over the years, our group developed a large biobank of patient- and cell-derived pediatric xenograft tumor models. We will test the selected top lead molecules in some of these pediatric sarcoma models in our future studies.
